The FGF family: biology, pathophysiology and therapy.
The family of fibroblast growth factors (FGFs) regulates a plethora of developmental processes, including brain patterning, branching morphogenesis and limb development. Several mitogenic, cytoprotective and angiogenic therapeutic applications of FGFs are already being explored, and the recent discovery of the crucial roles of the endocrine-acting FGF19 subfamily in bile acid, glucose and phosphate homeostasis has sparked renewed interest in the pharmacological potential of this family. This Review discusses traditional applications of recombinant FGFs and small-molecule FGF receptor kinase inhibitors in the treatment of cancer and cardiovascular disease and their emerging potential in the treatment of metabolic syndrome and hypophosphataemic diseases.
Beenken
Andrew
A
Department of Pharmacology, New York University School of Medicine, New York, New York 10016, USA. Andrew.Beenken@med.nyu.edu
Mohammadi
Moosa
M
D000818:Animals; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000503:physiopathology; D005346:Fibroblast Growth Factors / Q000378:metabolism / Q000627:therapeutic use*; D006706:Homeostasis / Q000502:physiology; D006801:Humans; D017674:Hypophosphatemia / Q000188:drug therapy / Q000503:physiopathology; D024821:Metabolic Syndrome / Q000188:drug therapy / Q000503:physiopathology; D009369:Neoplasms / Q000188:drug therapy / Q000503:physiopathology; D017468:Receptors, Fibroblast Growth Factor / Q000037:antagonists & inhibitors* / Q000378:metabolism
C117476:FGF19 protein, human; D017468:Receptors, Fibroblast Growth Factor; D005346:Fibroblast Growth Factors